
Deciphera Pharmaceuticals (DCPH) Stock Forecast & Price Target
Deciphera Pharmaceuticals (DCPH) Analyst Ratings
Bulls say
Deciphera Pharmaceuticals is expected to continue experiencing strong US sales growth due to off-label use in 2L GIST, along with price and treatment duration increases. With increased forecasts for both Qinlock sales and vimseltinib, along with a reiteration of their Buy rating and Price Target increase to $30, it is clear that analysts have a positive outlook on the company's financial performance.
Bears say
Deciphera Pharmaceuticals is facing several challenges, including declining cash reserves and a limited market presence due to contract negotiations. Additionally, their lead drug candidate has faced rejection from the EMA, adding further uncertainty to their growth potential in the near term. While they may have a chance at gaining approval for their other drug candidate in the EU market, it is still uncertain.
This aggregate rating is based on analysts' research of Deciphera Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Deciphera Pharmaceuticals (DCPH) Analyst Forecast & Price Prediction
Start investing in Deciphera Pharmaceuticals (DCPH)
Order type
Buy in
Order amount
Est. shares
0 shares